|
1
|
Aoki J, Taira A, Takanezawa Y, et al:
Serum lysophosphatidic acid is produced through diverse
phospholipase pathways. J Biol Chem. 277:48737–48744. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Contos JJ, Ishii I and Chun J:
Lysophosphatidic acid receptors. Mol Pharmacol. 58:1188–1196.
2000.PubMed/NCBI
|
|
3
|
Moolenaar WH: Bioactive lysophospholipids
and their G protein-coupled receptors. Exp Cell Res. 253:230–238.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye X, Ishii I, Kingsbury MA and Chun J:
Lysophosphatidic acid as a novel cell survival/apoptotic factor.
Biochim Biophys Acta. 1585:108–113. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu Y, Gaudette DC, Boynton JD, et al:
Characterization of an ovarian cancer activating factor in ascites
from ovarian cancer patients. Clin Cancer Res. 1:1223–1232.
1995.PubMed/NCBI
|
|
6
|
Siess W, Zangl KJ, Essler M, et al:
Lysophosphatidic acid mediates the rapid activation of platelets
and endothelial cells by mildly oxidized low density lipoprotein
and accumulates in human atherosclerotic lesions. Proc Natl Acad
Sci USA. 96:6931–6936. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maschberger P, Bauer M, Baumann-Siemons J,
et al: Mildly oxidized low density lipoprotein rapidly stimulates
via activation of the lysophosphatidic acid receptor Src family and
Syk tyrosine kinases and Ca2+ influx in human platelets.
J Biol Chem. 275:19159–19166. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Y, Xiao YJ, Baudhuin LM and Schwartz
BM: The role and clinical applications of bioactive lysolipids in
ovarian cancer. J Soc Gynecol Investig. 8:1–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H, Ye X, Mahanivong C, Bian D, Chun J
and Huang S: Signaling mechanisms responsible for lysophosphatidic
acid-induced urokinase plasminogen activator expression in ovarian
cancer cells. J Biol Chem. 280:10564–10571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smicun Y, Gil O, Devine K and Fishman DA:
S1P and LPA have an attachment-dependent regulatory effect on
invasion of epithelial ovarian cancer cells. Gynecol Oncol.
107:298–309. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Symowicz J, Adley BP, Woo MM, Auersperg N,
Hudson LG and Stack MS: Cyclooxygenase-2 functions as a downstream
mediator of lysophosphatidic acid to promote aggressive behavior in
ovarian carcinoma cells. Cancer Res. 65:2234–2242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Shen Z, Wiper DW, et al:
Lysophosphatidic acid as a potential biomarker for ovarian and
other gynecologic cancers. JAMA. 280:719–723. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
An S, Bleu T, Zheng Y and Goetzl EJ:
Recombinant human G protein-coupled lysophosphatidic acid receptors
mediate intracellular calcium mobilization. Mol Pharmacol.
54:881–888. 1998.PubMed/NCBI
|
|
14
|
Bandoh K, Aoki J, Hosono H, et al:
Molecular cloning and characterization of a novel human
G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol
Chem. 274:27776–27785. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hecht JH, Weiner JA, Post SR and Chun J:
Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid
receptor expressed in neurogenic regions of the developing cerebral
cortex. J Cell Biol. 135:1071–1083. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Im DS, Heise CE, Harding MA, et al:
Molecular cloning and characterization of a lysophosphatidic acid
receptor, Edg-7, expressed in prostate. Mol Pharmacol. 57:753–759.
2000.PubMed/NCBI
|
|
17
|
Noguchi K, Ishii S and Shimizu T:
Identification of p2y9/GPR23 as a novel G protein-coupled receptor
for lysophosphatidic acid, structurally distant from the Edg
family. J Biol Chem. 278:25600–25606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li W, Yu CP, Xia JT, et al: Sphingosine
kinase 1 is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 15:1393–1399. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shida D, Kitayama J, Yamaguchi H, et al:
Lysophosphatidic acid (LPA) enhances the metastatic potential of
human colon carcinoma DLD1 cells through LPA1. Cancer Res.
63:1706–1711. 2003.PubMed/NCBI
|
|
20
|
Yamashita H, Kitayama J, Shida D, et al:
Differential expression of lysophosphatidic acid receptor-2 in
intestinal and diffuse type gastric cancer. J Surg Oncol. 93:30–35.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohta H, Sato K, Murata N, et al: Ki16425,
a subtype-selective antagonist for EDG-family lysophosphatidic acid
receptors. Mol Pharmacol. 64:994–1005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Damirin A, Tomura H, Komachi M, et al:
Role of lipo-protein-associated lysophospholipids in migratory
activity of coronary artery smooth muscle cells. Am J Physiol Heart
Circ Physiol. 292:H2513–H2522. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gibbs JB: Mechanism-based target
identification and drug discovery in cancer research. Science.
287:1969–1973. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi JW, Herr DR, Noguchi K, et al: LPA
receptors: subtypes and biological actions. Annu Rev Pharmacol
Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murray D, Horgan G, Macmathuna P and Doran
P: NET1-mediated RhoA activation facilitates lysophosphatidic
acid-induced cell migration and invasion in gastric cancer. Br J
Cancer. 99:1322–1329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramachandran S, Shida D, Nagahashi M, et
al: Lysophosphatidic acid stimulates gastric cancer cell
proliferation via ERK1-dependent upregulation of sphingosine kinase
1 transcription. FEBS Lett. 584:4077–4082. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang R, Wang J, Ma S, Huang Z and Zhang
G: Requirement of Osteopontin in the migration and protection
against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901
cells. BMC Cell Biol. 12:112011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goetzl EJ, Dolezalova H, Kong Y, et al:
Distinctive expression and functions of the type 4 endothelial
differentiation gene-encoded G protein-coupled receptor for
lysophosphatidic acid in ovarian cancer. Cancer Res. 59:5370–5375.
1999.PubMed/NCBI
|
|
29
|
Shida D, Watanabe T, Aoki J, et al:
Aberrant expression of lysophosphatidic acid (LPA) receptors in
human colorectal cancer. Lab Invest. 84:1352–1362. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hope JM, Wang FQ, Whyte JS, et al: LPA
receptor 2 mediates LPA-induced endometrial cancer invasion.
Gynecol Oncol. 112:215–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu J, Lai YJ, Lin WC and Lin FT: TRIP6
enhances lysophosphatidic acid-induced cell migration by
interacting with the lysophosphatidic acid 2 receptor. J Biol Chem.
279:10459–10468. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang X, Yu S, Bast RC, et al: Mechanisms
for lysophosphatidic acid-induced cytokine production in ovarian
cancer cells. J Biol Chem. 279:9653–9661. 2004. View Article : Google Scholar : PubMed/NCBI
|
